Centrinone-B | CAS#1798871-31-4 | Plk4 inhibitor

MedKoo Cat#: 562388 | Name: Centrinone-B

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Centrinone-B is a reversible inhibitor of Polo-like kinase 4 (Plk4).

Chemical Structure

Centrinone-B

CAS#1798871-31-4

Theoretical Analysis

MedKoo Cat#: 562388

Name: Centrinone-B

CAS#: 1798871-31-4

Chemical Formula: C27H27F2N7O5S2

Exact Mass: 631.1483

Molecular Weight: 631.67

Elemental Analysis: C, 51.34; H, 4.31; F, 6.02; N, 15.52; O, 12.66; S, 10.15

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 350.00	2 Weeks
10mg	USD 650.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Centrinone-B; Centrinone B; CentrinoneB; LCR-323; LCR 323; LCR323;

IUPAC/Chemical Name

{2-[2-Fluoro-4-(2-fluoro-3-nitro-phenylmethanesulfonyl)-phenylsulfanyl]-5-methoxy-6-piperidin-1-yl-pyrimidin-4-yl}-(5-methyl-1H-pyrazol-3-yl)-amine

InChi Key

UPZNTUYHCRQOIQ-UHFFFAOYSA-N

InChi Code

InChI=1S/C27H27F2N7O5S2/c1-16-13-22(34-33-16)30-25-24(41-2)26(35-11-4-3-5-12-35)32-27(31-25)42-21-10-9-18(14-19(21)28)43(39,40)15-17-7-6-8-20(23(17)29)36(37)38/h6-10,13-14H,3-5,11-12,15H2,1-2H3,(H2,30,31,32,33,34)

SMILES Code

CC1=CC(NC2=NC(SC3=CC=C(S(=O)(CC4=CC=CC([N+]([O-])=O)=C4F)=O)C=C3F)=NC(N5CCCCC5)=C2OC)=NN1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 631.67 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Suri A, Bailey AW, Tavares MT, Gunosewoyo H, Dyer CP, Grupenmacher AT, Piper DR, Horton RA, Tomita T, Kozikowski AP, Roy SM, Sredni ST. Evaluation of Protein Kinase Inhibitors with PLK4 Cross-Over Potential in a Pre-Clinical Model of Cancer. Int J Mol Sci. 2019 Apr 29;20(9):2112. doi: 10.3390/ijms20092112. PMID: 31035676; PMCID: PMC6540285. 2: Denu RA, Shabbir M, Nihal M, Singh CK, Longley BJ, Burkard ME, Ahmad N. Centriole Overduplication is the Predominant Mechanism Leading to Centrosome Amplification in Melanoma. Mol Cancer Res. 2018 Mar;16(3):517-527. doi: 10.1158/1541-7786.MCR-17-0197. Epub 2018 Jan 12. PMID: 29330283; PMCID: PMC5835182. 3: Tkach JM, Philip R, Sharma A, Strecker J, Durocher D, Pelletier L. Global cellular response to chemical perturbation of PLK4 activity and abnormal centrosome number. Elife. 2022 Jun 27;11:e73944. doi: 10.7554/eLife.73944. PMID: 35758262; PMCID: PMC9236612. 4: Wong YL, Anzola JV, Davis RL, Yoon M, Motamedi A, Kroll A, Seo CP, Hsia JE, Kim SK, Mitchell JW, Mitchell BJ, Desai A, Gahman TC, Shiau AK, Oegema K. Cell biology. Reversible centriole depletion with an inhibitor of Polo-like kinase 4. Science. 2015 Jun 5;348(6239):1155-60. doi: 10.1126/science.aaa5111. Epub 2015 Apr 30. PMID: 25931445; PMCID: PMC4764081. 5: Singh CK, Denu RA, Nihal M, Shabbir M, Garvey DR, Huang W, Iczkowski KA, Ahmad N. PLK4 is upregulated in prostate cancer and its inhibition reduces centrosome amplification and causes senescence. Prostate. 2022 Jun;82(9):957-969. doi: 10.1002/pros.24342. Epub 2022 Mar 25. PMID: 35333404; PMCID: PMC9090996. 6: Fujimoto M, Bo T, Yamamoto K, Yasui H, Yamamori T, Inanami O. Radiation- induced abnormal centrosome amplification and mitotic catastrophe in human cervical tumor HeLa cells and murine mammary tumor EMT6 cells. J Clin Biochem Nutr. 2020 Nov;67(3):240-247. doi: 10.3164/jcbn.19-80. Epub 2020 Apr 9. PMID: 33293764; PMCID: PMC7705082. 7: Huang RL, Liu C, Fu R, Yan Y, Yang J, Wang X, Li Q. Downregulation of PLK4 expression induces apoptosis and G0/G1-phase cell cycle arrest in keloid fibroblasts. Cell Prolif. 2022 Jul;55(7):e13271. doi: 10.1111/cpr.13271. Epub 2022 Jun 7. PMID: 35670224; PMCID: PMC9251049. 8: Li J, Urabe G, Huang Y, Zhang M, Wang B, Marcho L, Shen H, Kent KC, Guo LW. A Role for Polo-Like Kinase 4 in Vascular Fibroblast Cell-Type Transition. JACC Basic Transl Sci. 2021 Mar 22;6(3):257-283. doi: 10.1016/j.jacbts.2020.12.015. PMID: 33778212; PMCID: PMC7987547.